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Abstract
Women have a consistently higher prevalence of major depressive disorder (MDD) than
men. Hypotheses implicating hypothalamic-pituitary -adrenal, -gonadal, and -thyroid axes,
immune response, genetic factors, and neurotransmitters have emerged to explain this dif-
ference. However, more evidence for these hypotheses is needed and new explanations
must be explored. Here, we investigated sex differences in MDDmarkers using multiplex
immunoassay measurements of 171 serum molecules in individuals enrolled in the Nether-
lands Study of Depression and Anxiety (NMDD = 231; Ncontrol = 365). We found 28 sex-
dependent markers of MDD, as quantified by a significant interaction between sex and log2-
transformed analyte concentration in a logistic regression with diagnosis (MDD/control) as
the outcome variable (p<0.05; q<0.30). Among these were a number of male-specific asso-
ciations between MDD and elevated levels of proteins involved in immune response, includ-
ing C-reactive protein, trefoil factor 3, cystatin-C, fetuin-A, β2-microglobulin, CD5L, FASLG
receptor, and tumor necrosis factor receptor 2. Furthermore, only male MDD could be clas-
sified with an accuracy greater than chance using the measured serum analytes (area
under the ROC curve = 0.63). These findings may have consequences for the generaliza-
tion of inflammatory hypotheses of depression to males and females and have important
implications for the development of diagnostic biomarker tests for MDD. More studies are
needed to validate these results, investigate a broader range of biological pathways, and
integrate this data with brain imaging, genetic, and other relevant data.
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Introduction
Major depressive disorder (MDD) is a highly prevalent and disabling condition with inade-
quate diagnosis and therapy [1]. In a recent WHOWorld Mental Health survey, the average
lifetime prevalence of MDD was found to be 14.6% in high-income countries and 11.1% in
middle- and low-income countries, with an approximately two-fold higher prevalence in
women compared to men [2]. A higher female prevalence of MDD has been observed consis-
tently across several countries and cultural settings from late adolescence onwards [3,4].
Several hypotheses implicate biological factors in the increased risk of MDD in females. Sex
hormones have been linked to the emergence of higher rates of female depression during
puberty and rising hormone levels during this time have been linked to affective disturbances
in girls [5,6]. Some evidence suggests that depressed females may show greater hypothalamic-
pituitary-adrenal (HPA) axis dysregulation than depressed males [7,8], while other evidence
suggests the reverse, with higher baseline levels of salivary cortisol found only in medication-
free depressed males [9] and in adolescent males who later developed clinical depression [10].
Extensive sex differences in immune response have also been documented [11] that may lead
to sex-dependent MDD pathophysiology [12]. Subclinical hypothyroidism has been proposed
to cause more MDD in females and is associated with reduced central serotonergic activity [5].
Other explanations may involve genetic factors and aspects of brain development and function
[13,14]. No consistent reason for the higher rate of MDD in females has been found.
Sex-dependent peripheral changes in biological processes in MDD have implications for the
development of biomarker tests. Biomarker tests to objectively diagnose MDD as part of a
screening programme, to identify individuals at high risk of developing the disorder [15], and
to help improve recognition and treatment of MDD in primary care settings [1] have been pro-
posed. Changes in peripheral inflammation, oxidative stress, metabolic markers, growth fac-
tors, and endocrine factors in MDD patients are potential biomarkers [16–19] for which
prominent sex differences have been found [11,20]. Sex differences in markers of MDD were
reported in the work of Domenici et al. (2010) [17], who found 11 plasma analytes with signifi-
cant interactions between sex and diagnosis, including growth hormone and proteins involved
in immune response. However, these were not evaluated as predictive markers.
We performed an extensive investigation of sex-dependent biomarkers of MDD in order to
help elucidate sex differences in the pathophysiology of MDD and explore their potential use
in diagnosis. This was done using serum molecular data from the baseline assessments of 1,243
individuals enrolled in the Netherlands Study of Depression and Anxiety (NESDA), a longitu-
dinal, multi-site naturalistic cohort study [21]. We analyzed 171 serum molecules measured
using a pre-selected multiplex immunoassay panel comprised of cytokines, hormones, growth
factors, metabolic markers, acute phase reactants, central nervous system markers, and others,
many of which have been linked to mental disorders [19,22–24]. These analyses will benefit the
development of diagnostic biomarker tests and further the understanding of molecular mecha-
nisms underlying the disorder in males and females.
Methods
An overview of the methods described in this section can be found in Fig 1.
Clinical samples
Clinical samples were from the Netherlands Study of Depression and Anxiety (NESDA), in
which 2,981 participants aged 18–65 years were recruited between 2004–2007 from the com-
munity (19%), general practices (54%), and mental health organizations (27%) [21] and fol-
lowed up. The study protocol for NESDA was approved by the Ethical Review Board of the VU
Sex Differences in SerumMDDMarkers
PLOS ONE | DOI:10.1371/journal.pone.0156624 May 27, 2016 2 / 18
PharmaPhenomics project (no. 0908). JMR was
funded by the Edmonton Churchill Scholarship and
the Cambridge Commonwealth Trust for the duration
of the study. FL is supported by a FP7-Marie Curie
Career Integration Grant (PCIG12-GA-2012-334065).
The infrastructure for the NESDA study (www.nesda.
nl) is funded through the Geestkracht program of the
Netherlands Organisation for Health Research and
Development (Zon-Mw, grant number 10-000-1002)
and is supported by participating universities and
mental health care organizations (VU University
Medical Center, GGZ inGeest, Arkin, Leiden
University Medical Center, GGZ Rivierduinen,
University Medical Center Groningen, Lentis, GGZ
Friesland, GGZ Drenthe, Scientific Institute for
Quality of Healthcare (IQ healthcare), Netherlands
Institute for Health Services Research (NIVEL), and
Netherlands Institute of Mental Health and Addiction
(Trimbos Institute). Cynthia Shannon Weickert (CSW)
is supported by Schizophrenia Research Institute
(utilising infrastructure funding from the NSW Ministry
of Health and the Macquarie Group Foundation), the
University of New South Wales, and Neuroscience
Research Australia. CSW is a recipient of a National
Health and Medical Research Council (Australia)
Senior Research Fellowship (#1021970).
Competing Interests: SB is a director of Psynova
Neurotech Ltd. JDC and SB were consultants for
Myriad-RBM until June 2014. This does not alter the
authors' adherence to PLOS ONE policies on sharing
data and materials.
Fig 1. Studymethods overview. A brief overview of the study methods is shown here, from sample collection to data analysis.Abbreviations: NESDA
(Netherlands Study of Depression and Anxiety); MDD (major depressive disorder); CMA (comorbid MDD and anxiety disorder(s)).
doi:10.1371/journal.pone.0156624.g001
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University Medical Centre and by local review boards at each participating centre (Ethical
Review Boards of the Leiden University Medical Centre and the Groningen University Medical
Centre). Informed written consent was given by all participants. Patients and controls were
excluded when not fluent in the Dutch language and when they had a primary clinical diagno-
sis of other psychiatric disorders not studied in NESDA: bipolar disorder, obsessive compulsive
disorder, severe substance use disorder, or psychotic disorder. In this study, serum samples and
data collected from the baseline assessment were used in analyses.
Diagnoses of depressive disorders (major depressive disorder (MDD) and dysthymia) and
anxiety disorders (social phobia, generalized anxiety disorder, panic disorder, and agorapho-
bia) were carried out during the baseline interview by specially trained research staff using the
Composite Interview Diagnostic Instrument (CIDI) in accordance with Diagnostic and Statis-
tical Manual of Mental Disorders (DSM)-IV criteria [25]. Patients with current disorders were
classified as having a depressive and/or anxiety episode within the past six months. Control
subjects had neither a current nor a lifetime diagnosis of the evaluated psychiatric disorders
and did not develop any assessed disorder by the second year follow-up assessment. Partici-
pants completed a 30-item self-rated Inventory of Depressive Symptomatology (IDS) [26] and
21-item self-report Beck Anxiety Inventory (BAI) [27]. History of MDD and anxiety disorders
and presence of first onset or recurrent MDD was determined with the CIDI. Family history of
depression or anxiety in first degree relatives was assessed [28], as well as antidepressant and
benzodiazepine use. These and other demographic, lifestyle, and health variables are further
described in S1 Table. A summary of these variables (stratified by sex) measured during the
baseline assessment is reported in S2 Table. Further details of the NESDA study design and
protocol have been previously described [21].
We categorized patients into three separate groups based on diagnosis at the baseline assess-
ment in order to reduce potential heterogeneity in sex differences between disorders. Individu-
als with MDD were currently experiencing an episode but were without a current comorbid
anxiety disorder. Individuals with comorbid MDD and anxiety disorder(s) (CMA) had both a
current MDD episode and at least one current anxiety disorder. Finally, remitted MDD
patients had a lifetime diagnosis of MDD, but were not currently experiencing MDD or an anx-
iety disorder. Individuals diagnosed with bipolar disorder and control subjects diagnosed with
MDD or anxiety disorder(s) at the second year follow-up assessment were excluded from fur-
ther analysis (see also Sample exclusion below) in order to obtain more homogeneous patient
and control groups. Diagnoses at the second year follow-up assessment were again carried out
using the CIDI.
Multiplex immunoassays
Blood samples from the NESDA baseline assessment were collected in the morning at approxi-
mately 0800 hours after an overnight fast. Only serum samples from the baseline assessment
were analyzed in this study. Serum samples were stored at –80°C until analysis. Protocol for the
study participants, collection and storage of clinical samples, and test methods were carried out
in compliance with the Standards for Reporting of Diagnostic Accuracy (STARD) initiative.
The Human DiscoveryMAP1multiplex immunoassay platform (Myriad RBM; Austin, TX,
USA) was used to measure the serum concentrations of 243 analytes. The Human Discovery-
MAP1 is a panel of pre-selected analytes designed to investigate a broad range of biological pro-
cesses important in diseases, including those commonly associated with cancer, cardiovascular
disease, kidney injury, neurodegenerative disorders, and inflammation and metabolic pathways
(https://rbm.myriad.com; accessed August 2015). S3 Table contains the list of all 243 measured
analytes. The data from this panel of markers was used to evaluate changes in analyte
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concentrations in MDD in NESDA (Bot et al. (2015) [19]). Sex-dependent analyses carried out
here complement the work of Bot et al (2015) [19], which used this data but did not examine
potential sex differences in markers. The panel was used to both explore markers that have pre-
viously been associated with MDD (e.g., cortisol, C-reactive protein, and thyroid stimulating
hormone) and to screen markers not yet investigated. The analytes were measured in 1,840
NESDA participants. Remaining baseline NESDA participants did not provide blood, did not
participate in the second year follow-up assessment, or had serum samples with insufficient vol-
ume or that were otherwise unusable. Of these, three samples were removed after internal qual-
ity control checks revealed poor quality. The assay procedure was carried out in a Clinical
Laboratory Improvement Amendments (CLIA)-certified laboratory at Myriad-RBM (Austin,
TX, USA). Samples were assigned to 26 plates and blinded to analysts using code numbers until
all biochemical assays were completed. Assays were calibrated using standards, raw intensity
measurements were converted to absolute protein concentrations, and performance was verified
using quality control samples. All analyte concentrations were reported as ng/mL, pg/mL or
international units (mIU), as appropriate. Average intra-assay variability was 5.6% (range from
2.5–15.8%) and inter-assay variability was 10.6% (range from 5.5–32.5%) [19].
Data pre-processing
Data pre-processing and analysis was carried out using R (v3.1.2) [29]. Analyte assays with
more than 30% missing values in the 1,837 samples were first removed. This resulted in exclu-
sion of 72 assays from the panel of 243, leaving 171 for further analysis. Among the excluded
assays was interleukin-6 (IL-6), for which 99.3% of values were below the limit of detection. A
list of all 243 analytes and the percentage of missing values contained in each assay can be
found in S3 Table. In addition, one sample was removed from the study which had more than
30% missing assays. Missing values for the remaining assays were replaced by the minimum or
maximum analyte level for measurements below or above the limit of quantitation, respec-
tively, as described previously [17,30]. Analyte values that were missing due to low sample vol-
ume were replaced by the mean concentration for that analyte. Results from this simple
method of missing data imputation were compared to those generated by multiple imputation
using the mice package in R [31]. For multiple imputation we used predictive mean matching
and Bayesian linear regression imputation techniques with five imputed datasets. We replaced
missing covariate data (physical activity: 5.0% missing, alcohol consumption: 0.8% missing,
and recreational drug use: 0.5% missing) with the mean or most frequent value for continuous
and categorical variables, respectively.
To adjust for batch effects caused by running samples on different plates, we used ComBat
after log2 transforming analyte data, implemented in the sva package in R [32]. ComBat is an
empirical Bayes method of adjusting for additive and multiplicative batch effects and has been
used in microarray data [33]. Multivariate outliers were then assessed based on a robust mea-
sure of the Mahalanobis distance [34] calculated using the robust package in R [35], resulting
in the removal of an additional four samples.
Sample exclusion
A total of 1,832 samples remained after data pre-processing. Additional samples were excluded
from analysis in this study for the following reasons, as shown in Fig 2: 1) the participants had
not fasted when blood was withdrawn (N = 44) or the participants were diagnosed with 2) cur-
rent or lifetime dysthymia only (N = 28); 3) current or lifetime anxiety disorder(s) only
(N = 384), 4) current minor depression (N = 12), 5) bipolar disorder (lifetime diagnosis) in the
second year follow-up assessment (N = 85), or 6) a depressive and/or anxiety disorder episode
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within two years of the baseline measurement (N = 36). This left 1,243 samples (405 males and
838 females) for further analysis. These comprised control (N = 365), MDD (N = 231), CMA
(N = 360), and remitted MDD (N = 287) samples.
Data analysis
We used logistic regression with patient/control status as the outcome variable to test for sex
differences in the associations between log2-transformed analyte concentration and log-odds of
MDD diagnosis, as indicated by a significant interaction between log2-transformed analyte
level and sex (p<0.05; sex-dependent markers). Other variables were also considered in analy-
ses, including: ancestry, education, diastolic blood pressure, physical activity [36], family his-
tory of anxiety or depression [28], presence of chronic disease, use of lipid modifying agents,
use of anti-inflammatory drugs, use of antihypertensive medication, collection area, BMI, age,
alcohol consumption, smoking status, recreational drug use, partner status, and hormonal
Fig 2. Sample exclusion for NESDA patient groups and controls after data pre-processing. Numbers are indicated in brackets. Red boxes = initial
data after pre-processing; blue boxes = excluded data; green boxes = data after exclusion. Participants were excluded if they were not fasting or if they
had a current/lifetime anxiety disorder or dysthymia only, current minor depression, a depressive and/or anxiety diagnosis within two years of the baseline
measurement, or a lifetime bipolar disorder diagnosed at the two-year assessment. Abbreviations: NESDA (Netherlands Study of Depression and
Anxiety); MDD (major depressive disorder); CMA (comorbid MDD and anxiety disorder(s)).
doi:10.1371/journal.pone.0156624.g002
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status (follicular phase of the menstrual cycle/luteal phase/use of OCs/postmenopausal status/
other), as well as interactions between them and sex. These variables are further described in
the S1 Table and summarized in S2 Table. They were selected using simultaneous forward and
backward stepwise selection using Bayesian Information Criterion (BIC) selection criterion.
Analytes with significant sex-analyte interaction terms (p<0.05; sex-dependent markers) were
tested separately in males and females and classified as either male-specific, female-specific, or
qualitative markers. Male-specific markers had serum concentrations that were significantly
associated with log-odds of MDD in males only (p<0.05 in males, p>0.20 in females) and
female-specific markers were significant in females only (p<0.05 in females, p>0.20 in males).
Serum levels of qualitative markers had opposite associations with log-odds of MDD diagnosis
between males and females (i.e., reduced levels of an analyte in males and increased levels of an
analyte in females were associated with higher log-odds of MDD or vice versa; see S1 Appendix
for a fuller description of logistic regression). Adjusted p-values were calculated to account for
multiple testing using the Benjamini and Hochberg (1995) [37] false discovery rate (FDR) pro-
cedure and were reported for all analyses. These FDR-adjusted p-values are reported as q-val-
ues. It should be noted that FDR-based multiple testing correction procedures are less
conservative than procedures to control the family-wise error rate [38]. We used the same pro-
cedure to examine sex-dependent markers of CMA and remitted MDD. The same control sub-
jects were used as the reference population for MDD, CMA, and remitted MDD analyses. Gene
ontology biological process terms for significant proteins were assessed using the UniProt web-
site (www.uniprot.org; accessed June 2015) and European Bioinformatics Institute’s QuickGO
online database (www.ebi.ac.uk/QuickGO; accessed June 2015). The overlap between our
serum findings, analytes with significantly different concentrations between MDD patients and
controls from Bot et al. (2015) [19], and plasma analytes with significant interactions between
sex and diagnosis (MDD or control) in the work of Domenici et al. (2010) [17] were also evalu-
ated. Domenici et al. (2010) [17] measured 79 analytes in the plasma of MDD patients and con-
trols and found 11 plasma analytes with significant sex-dependent differences in concentration
between patients and controls. Plasma analytes measured in Domenici et al. (2010) are listed in
S3 Table.
Joint analyses and classification
We used a logistic regression model with forward stepwise selection using BIC [39] to define a
set of analytes for classification of MDD for males and females separately. Analytes were
selected from all 171 measured and retained after quality control. In order to assess the unbi-
ased performance of the male and female models in classifying new observations, a repeated
ten-fold cross-validation procedure was performed [40], followed by plotting the receiver oper-
ating characteristic (ROC) curve and measuring the area under the ROC curve (AUC). For the
ten-fold cross-validation [39], the data was randomly divided into ten partitions stratified by
MDD diagnosis using the sample function in the base package in R. Nine partitions were used
to create a logistic regression model using forward stepwise selection with BIC of all analytes.
This was then used to estimate the probability of MDD diagnosis for the observations in the
last partition. This was repeated for each of the remaining partitions. The entire process of ran-
domly dividing the data into stratified partitions, building the model using nine partitions, and
evaluating in the last was done 50 times for each male and female model. This provided a better
estimate of the average of all possible different splits into ten partitions [40]. Each ROC curve
from the 50 repeated ten-fold cross-validations was plotted and a Wilcoxon test was used to
assess whether the AUC was greater than 0.50 (performance expected by randomly guessing a
class) [41]. An average ROC curve was then generated by merging all test sets into one large set
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[42] and the median p-value fromWilcoxon tests of the AUC was found. ROC curves were
generated and AUCs were calculated using the ROCR package [43] in R. Wilcoxon tests were
performed using the verification package in R [44].
Results
In the NESDA cohort, females were overrepresented in the MDD (65%), CMA (72%), remitted
MDD (71%), and control (62%) classifications (S2 Table). MDD, CMA, and remitted patients
had significantly higher diastolic blood pressure and were more likely than controls to suffer
from a chronic disease, use anti-inflammatory medication, smoke, and have a family history of
depression or anxiety. There were no significant differences between males and females in
MDD type (first episode or recurrent), benzodiazepine or antidepressant use, IDS or BAI
scores, or presence of lifetime anxiety disorder diagnosis in MDD, CMA, or remitted MDD.
Twenty-eight analytes were sex-dependent markers of MDD, as defined by a significant
interaction (p<0.05) between log2-transformed serum concentration and sex in the logistic
regression analysis of MDD patients and controls. Results are illustrated graphically in Fig 3
and in tabular form for both simple and multiple imputation in S4 Table. After adjusting p-val-
ues for multiple testing, these interactions were also all significant at q<0.30 and eight were sig-
nificant at q<0.10 [trefoil factor 3 (TFF3), C-reactive protein (CRP), CD5 antigen-like (CD5L),
IGFBP-4, β2-microglobulin (B2M), osteoprotegerin (OPG), tumor necrosis factor receptor 2
(TNFR2), and fetuin-A in order of decreasing significance]. Q-values greater than 0.10 were
obtained for 20 of the results, with nine additional analytes significant at q<0.20 [urokinase-
type plasminogen activator receptor (uPAR), vascular cell adhesion molecule 1 (VCAM-1),
factor VII, cystatin-C, myoglobin, fatty acid-binding protein (FABP) (adipocyte), FASLG
receptor (FAS), thyroxine-binding globulin (TBG), and eotaxin-1] and the remaining 11 signif-
icant at higher q-values of less than 0.30 [C-peptide, hepatocyte growth factor (HGF) receptor,
vonWillebrand factor (vWF), macrophage derived chemokine (MDC), pancreatic polypeptide
(PPP), macrophage inflammatory protein-3β (MIP-3B), pulmonary and activation-regulated
chemokine (PARC), matrix metalloproteinase-7 (MMP-7), insulin-like growth factor binding
protein (IGFBP)-5, tenascin-C (TN-C), and interleukin-2 receptor α (IL-2RA)]. Results were
qualitatively similar to those generated using multiple imputation for analytes with missing val-
ues (S4 Table). However, it should be noted that one analyte (eotaxin-1) was no longer signifi-
cant when analyzed using multiple imputation. IGFBP-5, MIP-3B, and IL-2RA were the only
female-specific markers, with lower serum levels associated with increased odds of MDD in
females only. IGFBP-5 participates in biological processes including cell growth, glucose
metabolism, and signal transduction, while MIP-3B and IL-2RA are involved in inflammatory
response and regulation of T cell proliferation. Of the remaining 25 analytes, 12 were male-spe-
cific and 13 had a qualitative interaction. With the exception of HGF receptor and eotaxin-1,
higher levels of male-specific analytes and analytes with qualitative interactions were associated
with increased odds of MDD in males compared to females. Many of these are involved in
defence, inflammatory, and immune response [TFF3, B2M, fetuin-A, cystatin-C, FABP (adipo-
cyte), CRP, CD5L, VCAM-1, TNFR2, FAS, eotaxin-1, C-peptide, MDC, PARC, and MMP-7].
Others, including IGFBP-4, HGF receptor, vWF, uPAR, TBG, PPP, TN-C, OPG, factor VII,
and myoglobin, participate in a variety of biological processes. Among these are blood coagula-
tion, apoptosis, signal transduction, cell adhesion, oxygen transport, regulation of cell growth,
glucose metabolism, regulation of appetite, and skeletal system development. Only five analytes
(TFF3, IGFBP-4, factor VII, myoglobin, and FAS) with significant interactions between sex
and log2-transformed analyte concentration in the CMA/control and four (TFF3, B2M, factor
VII, and MIP-3B) in the remitted MDD/control comparisons overlapped with the 28
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Fig 3. Analytes with significant interactions between log2-transformed serum concentration and sex in MDD compared to controls. The natural
logarithm of the odds ratio (OR; the ratio of the odds of MDD diagnosis associated with a two-fold increase in the untransformed serum concentration of
that analyte from the logistic model) is shown for males and females with 95% confidence intervals. P- and q-values (FDR-adjusted p-values) are shown
for the interaction tests. Abbreviations:OR (odds ratio); Q (q-value, FDR-adjusted p—value); TFF3 (trefoil factor 3); IGFBP (insulin-like growth factor
binding protein); B2M (β2-microglobulin); uPAR (urokinase-type plasminogen activator receptor); FABP (fatty acid-binding protein); TBG (thyroxine-
binding globulin); HGF (hepatocyte growth factor); vWF (vonWillebrand factor); PPP (pancreatic polypeptide); TN-C (tenascin-C); CRP (C-reactive
protein); CD5L (CD5 antigen-like); OPG (osteoprotegerin); TNFR2 (tumor necrosis factor receptor 2); VCAM (vascular cell adhesion molecule); FAS
(FASLG receptor); MDC (macrophage derived chemokine); PARC (pulmonary and activation-regulated chemokine); MMP (matrix metalloproteinase);
MIP-3B (macrophage inflammatory protein-3β); IL-2RA (interleukin-2 receptor α). † Eotaxin-1 was no longer significant when analyzed using multiple
imputation (see S4 Table).
doi:10.1371/journal.pone.0156624.g003
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significant analytes in the MDD/control comparisons (see Fig 4 and S5 Table). Two sex-depen-
dent markers, TFF3 and factor VII, overlapped with all three conditions (MDD, CMA, and
remitted MDD).
We compared these results to those of Bot et al. (2015) [19], who found 19 analytes with sig-
nificantly different serum concentrations between controls and MDD patients without comor-
bid anxiety disorder(s) in this NESDA molecular data. Five analytes found to differ between
MDD patients and controls in the work of Bot et al. (2015) [19] (cystatin-C, FABP (adipocyte),
fetuin-A, IGFBP-5, and PPP) were rather found to be sex-dependent markers of MDD in this
study, meaning their association with the disorder was different in males and females. Dome-
nici et al. (2010) [17] measured nine plasma analytes that overlapped with our 28 findings in
serum. One of our sex-dependent markers (MDC) also had a significant sex-diagnosis interac-
tion (p-value< 0.05) in Domenici et al. (2010) [17]. Two more of our sex-dependent markers
(TBG and vWF) had sex-diagnosis interaction p-values< 0.10 in Domenici et al. (2010) [17].
Next, logistic regression models were fit for classification of current MDD compared to con-
trols for males and females separately, using forward stepwise selection of the 171 measured
analytes. Two analytes were selected for female classification (CD5L and IGFBP-5), and five
were selected for male classification (TFF3, angiogenin, transthyretin, HGF receptor, and epi-
dermal growth factor (EGF) receptor). The classification performances of the forward stepwise
selection logistic regression models were then evaluated. Based on average ROC curves from
the 50 repeated ten-fold cross-validations, an AUC of 0.63 was found for male classification
(median p-value of tests 6E-04) and an AUC of 0.50 was found for female classification
Fig 4. Analytes with overlapping significant interactions between sex and log2-transformed serum concentration in MDD and (A) CMA and (B)
remitted MDD compared to controls. The natural logarithm of the odds ratio (OR; ratio of the odds of diagnosis associated with a two-fold increase in
the untransformed serum concentration of that analyte from the logistic model) is shown for males and females with 95% confidence intervals. P- and q-
values (FDR-adjusted p-values) are shown for the interaction tests. Analytes are plotted in the same order as Fig 3. Abbreviations: CMA (comorbid
MDD and anxiety disorder(s)); OR (odds ratio); Q (q-value, FDR-adjusted p—value); TFF3 (trefoil factor 3); IGFBP (insulin-like growth factor binding
protein); B2M (β2-microglobulin); FAS (FASLG receptor); MIP-3B (macrophage inflammatory protein-3β).
doi:10.1371/journal.pone.0156624.g004
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(median p-value of tests 0.48). These average ROC curves for males and females and the ana-
lytes selected using forward stepwise selection are shown in Fig 5. Plots of all 50 ROC curves
from ten-fold repeated cross-validations for males and females can also be found in S1 Fig.
Discussion
This study identified a number of sex-dependent serum markers of MDD in a large, well-
characterized cohort. Previous studies have measured only a few molecules at a time testing
specific hypotheses, assessed limited information about participants, and/or studied specific
patient populations. NESDA provides extensive information on a number of serum analytes
and sample characteristics from a large cross-section of the patient population from the com-
munity, primary care, and specialized health care settings. Importantly, it also assesses female
hormonal status, comorbid disorders, and follow-up diagnoses. Previously, Bot et al. (2015)
[19] showed that the serum concentrations of 19 molecules differed between MDD patients
without comorbid anxiety disorder(s) and controls, including five (cystatin-C, FABP (adipo-
cyte), fetuin-A, IGFBP-5, and PPP) found here to be sex-dependent markers. In total, we
identified 28 sex-dependent markers of MDD, demonstrating that sex plays an important role
in the molecular heterogeneity of MDD and that these interactions should be assessed in bio-
marker studies of the disorder.
Fig 5. ROC curve illustrating classification of MDD patients from controls for males and females using repeated ten-fold
cross validation of logistic regression with BIC forward stepwise selection of all analytes. The legend shows AUCs and
median p-values of tests on repeated cross validations in brackets. Markers selected in forward stepwise selection of log2-
transformed analyte data are shown in the right panel. Abbreviations: AUC (area under the ROC curve); P (median p-value); MDD
(major depressive disorder); CD5L (CD5 antigen-like); IGFBP (insulin-like growth factor binding protein); TFF3 (trefoil factor 3); HGF
(hepatocyte growth factor); EGF (epidermal growth factor).
doi:10.1371/journal.pone.0156624.g005
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The present study found strong evidence to support a link between MDD and elevated levels
of certain proteins involved in immune response specifically in males, including CRP, TFF3,
cystatin-C, fetuin-A, β2-microglobulin, CD5L, FAS, and TNFR2. These results had q-values
less than 0.10, with the exception of FAS and cystatin-C. The association between elevated
CRP and male MDD confirms the findings of a previous NESDA and other large cohort stud-
ies, including a meta-analysis of CRP in depression [45–49]. Other findings, however, were
novel and provide further evidence of more inflammatory processes occurring in male com-
pared to female MDD. Increased serum levels of these molecules have been found in low grade
inflammation and autoimmune disease and are implicated in the function of T-cells, mono-
cytes, and macrophages [50–57].
These findings may have consequences for hypotheses of depression proposing that inflam-
mation causes the behavioural, neuroendocrine, and neurochemical changes in MDD [58,59].
Consistent with extensive sex differences in immune function [11], the results of this study
indicate that this causal mechanism could be sex-dependent. Males may be more prone to dys-
regulation of acute inflammation and pro-inflammatory immune response, as suggested by the
higher prevalence of males with autoimmune diseases with these characteristics [60] (despite a
higher overall prevalence of autoimmune diseases in females) and greater male susceptibility to
infection. Toker et al. (2005) have also suggested that stress pathways may influence inflamma-
tory processes differently in males and females. Other lines of evidence point to parallel male-
specific disruptions in inflammation in mental disorders. First-onset antipsychotic naive
schizophrenia [24] and Asperger syndrome [23,61] have also been characterized by male-spe-
cific elevations in the serum concentrations of inflammatory molecules. Complex bidirectional
relationships between depression and inflammation have been observed and further work will
be required to elucidate the mechanisms involved.
In contrast to male findings, few female-specific MDDmarkers were found and these had
high q-values. Female-specific MDDmarkers may have provided greater insight into the bio-
logical basis for its higher prevalence in females. There were no significant sex-dependent asso-
ciations between total serum cortisol levels and MDD that would provide an indication of sex
differences in HPA axis dysfunction, as found in previous studies [7–10]. There were also no
sex differences in associations between MDD and thyroid stimulating hormone that may have
indicated a greater prevalence of subclinical hypothyroidism in female MDD patients, as has
been previously hypothesized [5]. Furthermore, female MDD classification using molecular
data was no more accurate than chance (AUC = 0.50). Variability in female molecular levels
may be higher or female MDDmay be more biologically heterogeneous than male MDD, mak-
ing biomarker discovery more difficult.
Few sex-dependent markers of CMA overlapped with sex-dependent markers of MDD, sug-
gesting that different sex-dependent pathophysiological mechanisms may be involved in MDD
and CMA. Studies should consider the presence of comorbid anxiety disorder(s) in future
investigations of sex differences in MDD. Heterogeneity of anxiety disorders may contribute to
these differences. Furthermore, most sex differences in MDDmarkers were only present during
an episode and did not persist in remitted MDD. Similarly, Bot et al. (2015) [19] found changes
in serum analyte levels to be more pronounced in current MDD compared to remitted MDD.
Only two markers (TFF3 and factor VII) were significant sex-dependent markers in all three
conditions (MDD, CMA, and remitted MDD).
Despite detecting a number of sex-dependent markers, the performance of male and female
MDD classification based on serum molecular concentrations in this study was not adequate
for use as a diagnostic tool. An objective biomarker test for MDD could provide earlier diagno-
sis and improve recognition of the disorder by physicians in primary care settings [1]. How-
ever, molecular measurements could not be used to separate female MDD patients from
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controls (AUC = 0.50). Male MDD patients were classified from controls with an accuracy
slightly higher than chance (AUC = 0.63), raising the possibility that these could be used with
other data to aid in diagnosis. These results contradicted the findings of Papakostas et al.
(2013) [18] / Bilello et al. (2015) [62] and Domenici et al. (2010) [17]. Papakostas et al. (2013)
[18] and Bilello et al. (2015) [62] used a panel of nine serum markers that were also measured
in our study (α1-antitrypsin, apolipoprotein CIII, brain-derived neurotrophic factor, cortisol,
epidermal growth factor, myeloperoxidase, prolactin, resistin and TNFR2) to achieve a test
accuracy of 91% (AUC = 0.93) in separating MDD patients from controls. Domenici et al.
(2010) [17] used ten plasma markers (nine of which overlapped with those measured in our
serum study) and reported approximately 80% sensitivity and 75% specificity for classifying
MDD patients from controls. Clearly, more work is needed to resolve these discrepancies and
establish an accurate, reproducible biomarker signature for male and female MDD.
Certain limitations and future work should be considered. First, more studies are needed to
validate these results given the high q-values obtained for many of the findings. Next, more
work is needed to determine mechanisms by which these findings arise and investigate a
broader range of biological pathways than is presently covered in the multiplex immunoassay
panel. Although a number of inflammatory markers were evaluated, IL-6 could not be investi-
gated here since most measurements were below the limit of detection. IL-6 is an important,
well-researcher marker of inflammation that has shown a positive association with depression
[49] and should be examined in future studies. Most of the sex-dependent markers of MDD in
this work did not overlap with analytes found to have significant sex-diagnosis interactions in
Domenici et al. (2010) [17]. This may be due to the investigation of plasma biomarkers instead
of serum, the use of different statistical analyses, or the inclusion of only recurrent patients
with and without comorbid anxiety disorders in Domenici et al. (2010) [17]. Second, although
the present study analyzed current CMA separately, the number of different anxiety disorders
included in the study and the high comorbidity between them prevented further investigation
of sex differences in markers of specific anxiety disorders comorbid with MDD. Future studies
should further investigate the influence of these and other features of MDD on sex-dependent
markers of depression, such as prior anxiety disorder diagnoses, chronicity of MDD, and atypi-
cal and melancholic features. This may improve the classifier performance of biomarker tests.
Finally, integration of this molecular data with brain imaging, genetic, and other relevant data
would enable investigators to consider a greater number of factors thought to influence the
higher prevalence of female MDD.
This study presents a step forward in understanding sex differences in MDD and has impor-
tant implications for future studies. We found distinct differences between males and females
in serum molecular markers of MDD, including male-specific associations between MDD and
elevated levels of immune molecules. These findings may have consequences for inflammatory
hypotheses of depression in males and females. Males may be more prone to an inflammatory
basis of depression than females or inflammatory mechanisms in depression may differ
between the sexes. Despite finding a number sex-dependent markers the classification accuracy
of MDD using the measured molecules was low and only male MDD patients were classified
with an accuracy higher than chance. Future studies of MDD will need to resolve discrepancies
between the accuracies of biomarker tests produced from different studies. Robust tests may
need to use different biomarkers for males and females. Finally, most sex-dependent serum
molecular associations were not consistent across MDD, CMA, and remitted MDD. Sex differ-
ences in MDDmarkers may be state-dependent and presence of comorbid anxiety disorder(s)
should be taken into account in future biomarker studies.
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Supporting Information
S1 Appendix. Further description of logistic regression model.
(PDF)
S1 Fig. ROC curves from the 50 repeated ten-fold cross-validations illustrating classifica-
tion of MDD patients from controls for males (A) and females (B). Bold, dotted lines are
average ROC curves from Fig 5 in the main text.
(TIF)
S1 Table. Description of variables. It should be noted that medication use was evaluated by
self-reporting and inspection of drug containers used in the past month. Abbreviations: ATC
(Anatomical Therapeutic Chemical).
(PDF)
S2 Table. Female (A) and male (B) demographic, health, and lifestyle characteristics for
MDD, CMA, and remitted MDD patients and controls. Values are shown as mean ± the
standard deviation. Differences between controls and conditions were assessed using Welch's
t-test (continuous data) or Fisher's exact test (categorical data). Variables in bold were signifi-
cantly different (p<0.05) from controls. Abbreviations: MDD (major depressive disorder);
CMA (comorbid MDD and anxiety disorder(s)); BMI (body mass index); MET (metabolic
equivalent); OC (oral contraceptive); TCA (tricyclic antidepressant); SSRI (selective serotonin
reuptake inhibitor).
(PDF)
S3 Table. List of serum molecules measured with multiplex immunoassay. Analytes ana-
lyzed in this study (i.e., with<30%missing assay values) are marked in a✓. Analytes measured
in plasma in the work of Domenici et al. (2010) are marked with a✓ in the last column.
(PDF)
S4 Table. Analytes with significant interactions between log2-transformed serum concen-
tration and sex in MDD compared to controls (A) and a comparison with results using
multiple imputation (B). In (A), a simple missing value imputation method was used (see
main text). In (B), interaction p-values from multiple imputation are also presented for assays
with missing values using predictive mean matching and Bayesian linear regression imputation
techniques (see also main text). Odds ratios (OR) represent the ratio of odds of MDD diagnosis
associated with a two-fold increase in the untransformed serum concentration of that analyte
from the logistic model. Ratio (R) represents the ratio between the geometric means of patient
and control analyte concentrations. Orange boxes = male-specific analytes; white
boxes = analytes with a qualitative interaction; blue boxes = female-specific analytes. Abbrevia-
tions: R (ratio, patient/control); OR (odds ratio); P (p-value); Q (q-value); TFF3 (trefoil factor
3); IGFBP (insulin-like growth factor binding protein); B2M (β2-microglobulin); uPAR (uroki-
nase-type plasminogen activator receptor); FABP (fatty acid-binding protein); TBG (thyrox-
ine-binding globulin); HGF (hepatocyte growth factor); vWF (von Willebrand factor); PPP
(pancreatic polypeptide); TN-C (tenascin-C); CRP (C-reactive protein); CD5L (CD5 antigen-
like); OPG (osteoprotegerin); TNFR2 (tumor necrosis factor receptor 2); VCAM (vascular cell
adhesion molecule); FAS (FASLG receptor); MDC (macrophage derived chemokine); PARC
(pulmonary and activation-regulated chemokine); MMP (matrix metalloproteinase); MIP-3B
(macrophage inflammatory protein-3β); IL-2RA (interleukin-2 receptor α).
(PDF)
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S5 Table. Analytes with overlapping significant interactions between sex and log2-trans-
formed serum concentration in MDD and (A) CMA and (B) remitted MDD compared to
controls. Odds ratios (OR) represent the ratio of odds of the condition associated with a two-
fold increase in the untransformed serum concentration of that analyte from the logistic
model. Ratio (R) represents the ratio between the geometric means of patient and control ana-
lyte concentrations. Abbreviations: R (ratio, patient/control); OR (odds ratio); P (p-value); Q
(q-value); MDD (major depressive disorder); CMA (comorbid MDD and anxiety disorder(s));
IGFBP (insulin-like growth factor binding protein); FAS (FASLG receptor); TFF3 (trefoil factor
3); MIP-3B (macrophage inflammatory protein-3β); B2M (β2-microglobulin).
(PDF)
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